Big Tex:
Couple weeks ago said SGNC on move. No reason found until today. Has tripled since then and could be one of biggest baggers of all time even at this leve. No guarantees.
I still own a little SGNC from way back. I really am staying away from pennies but here is news. Prospecter, please don't go into senseless jabber mode flooding the thread with nonsense and I may even bookmark it again.
Sanguine Corp. Releases Letter to Shareholders
Business Editors
PASADENA, Calif.--(BUSINESS WIRE)--Dec. 14, 1999--The following
was issued to shareholders by Sanguine Corp. (OTC BB: SGNC):
Dec. 14, 1999
Dear Shareholder,
Recently, the company has been in negotiations to fund the
continuation of the clinical trials for animal safety and efficacy for
PHER-O2, a synthetic red blood cell. We expect to have good news in
this regard in the near future.
Upon funding, the clinical trials will be conducted by Battelle,
the largest independent research group, for submission to the United
States Food and Drug Administration (FDA) for approval.
One of the most interesting features of Sanguine is that we
anticipate rapid FDA approval, since PHER-O2 is a second-generation
drug. Also we do not believe we will have to build a factory as there
is ample emulsification manufacturing capacity in the drug industry.
The present emulsified products are very low profit items, i.e.
parenteral nutritional, and we can easily replace them with PHER-O2,
which is high profit to the manufacturer and Sanguine. Sterile
intravenous capacity is also readily available for filling plastic
blood bags.
Battelle will proceed with our animal trials and M.D.S. Harris
will conduct human clinical trials. Both have committed to complete
these second-generation trials in a total of 3 years versus the usual
average of 10 to 20 years, because our synthetic red blood cells are a
second-generation drug.
Sincerely,
Thomas C. Dress, MBA, Ph.D.
Chairman and CEO
Notice: This news release contains, and oral statements made from
time to time by company representatives concerning the information
contained herein may contain so-called "forward-looking statements."
These statements can be identified with introductory words such as
"expects," "plans," "will," "estimates," "forecasts," "projects" or
words of similar meaning, and by the fact that they do not relate
strictly to historical or current facts.
Forward-looking statements frequently are used in discussing the
company's growth strategy, operating and financial goals, regulatory
submissions and approvals and development programs.
Many factors may cause actual results to differ from the
company's forward-looking statements, including inaccurate assumptions
and a broad variety of risks and uncertainties, some of which are
known and others of which are not. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing
undue reliance on such statements.
--30--lma/ix*
CONTACT: Sanguine Corp., Pasadena
Thomas C. Dress, 818/405-0079
Fax: 818/405-1041
KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
FROM: SGNC SI thread. Good Luck --GARY-- |
